NASHVILLE, Tenn., March 3, 2021 /PRNewswire/ -- Cryoport, Inc.
(NASDAQ: CYRX) ("Cryoport" or the "Company"), a global leader in
temperature-controlled supply chain solutions for the life sciences
industry, today announced its Board of Directors has elected
Linda Baddour as a member of the
Board, effective March 15, 2021.
Linda Baddour is a senior executive
with over twenty years of experience in healthcare, life sciences
and pharmaceuticals.
"Our corporate governance underpins all that we do at Cryoport
and we are delighted to strengthen our Board as we leverage our
newly expanded global footprint and advanced temperature-controlled
supply chain platform to spur our growth," said Jerrell Shelton, CEO of Cryoport.
"Linda's deep healthcare experience gained from her leadership
role scaling PRA Health Sciences, a global contract research
organization and data science company, will be a valuable addition
to our Board of Directors," added Dr. Ram Mandalam, Chairman of the
Nominating and Governance Committee.
Linda Baddour stated, "Cryoport's
reputation as a provider of innovative, high quality and reliable
temperature-controlled supply chain solutions for the life sciences
has made it a clear leader in the life sciences industry, and
especially within the Biopharma/Pharma market. There are currently
an increasing number of regenerative therapies that are entering
development, progressing through clinical trials and approaching
commercialization and Cryoport has a unique opportunity to achieve
outsized growth by scaling its operations within this rapidly
growing market. It is an incredibly exciting time to join Cryoport
and I look forward to bringing my experience to the Board to help
drive forward this strategy."
Ms. Baddour has served on the Board of Directors of Waters
Corporation, a publicly traded analytical laboratory instrument and
software company, since 2018 as well as two Genstar Capital
portfolio companies, Advarra since 2019 and Signant Health, since
2020. From 2007 to 2018, Ms. Baddour served as
Executive Vice President and Chief Financial Officer of PRA Health
Sciences, a global contract research organization and data science
company. During Ms. Baddour's tenure, PRA Health Sciences grew from
approximately 3,000 employees to over 17,000. From 1995 to 2007,
Ms. Baddour worked at Pharmaceutical Product Development, Inc.,
serving as Chief Financial Officer, Treasurer and Chief Accounting
Officer. Ms. Baddour earned both a B.A. and M.B.A. from the
University of North Carolina at
Wilmington and is a certified public accountant.
About Cryoport, Inc.
Cryoport, Inc. (Nasdaq: CYRX) is redefining
temperature-controlled supply chain support for the
life sciences industry by continually broadening its platform of solutions and services, serving the
Biopharma, Reproductive Medicine, and Animal Health markets. Through its family of companies,
Cryoport Systems, MVE Biological Solutions, CRYOPDP and CRYOGENE,
Cryoport provides strategic solutions that support the growing
needs of these markets.
Forward-Looking Statements
Statements in this press release which are not purely
historical, including statements regarding the Company's
intentions, hopes, beliefs, expectations, representations,
projections, plans or predictions of the future, are
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. These forward-looking
statements include, but are not limited to, those related to the
Company's industry, business, plans, strategy, acquisitions,
including CRYOPDP and MVE Biological Solutions, financial results
and financial condition. It is important to note that the
Company's actual results could differ materially from those in any
such forward-looking statements. Factors that could cause actual
results to differ materially include, but are not limited to, risks
and uncertainties associated with the effect of changing economic
conditions, trends in the products markets, variations in the
Company's cash flow, market acceptance risks, and technical
development risks. The Company's business could be affected by a
number of other factors, including the risk factors discussed in
the Company's Securities and Exchange Commission ("SEC") reports
including, but not limited to, the Company's Annual Report on Form
10-K for the three and twelve months ended December 31, 2020 and any subsequent filings with
the SEC. The forward-looking statements contained in this press
release speak only as of the date hereof and the Company cautions
investors not to place undue reliance on these forward-looking
statements. Except as required by law, the Company disclaims any
obligation, and does not undertake to update or revise any
forward-looking statements in this press release.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/cryoport-announces-appointment-of-linda-baddour-to-its-board-of-directors-301240058.html
SOURCE Cryoport, Inc.